Adverse events4,452

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 4,452

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Phase 2: Placebo	0	156	0
other	Anaemia	Blood and lymphatic system disorders	Phase 2: 700 mg Bamlanivimab	0	101	0
other	Anaemia	Blood and lymphatic system disorders	Phase 2: 2800 mg Bamlanivimab	0	107	0
other	Anaemia	Blood and lymphatic system disorders	Phase 2: 7000 mg Bamlanivimab	0	101	0
other	Anaemia	Blood and lymphatic system disorders	Phase 2: 2800 mg Bamlanivimab + 2800 mg Etesevimab	0	112	0
other	Anaemia	Blood and lymphatic system disorders	Phase 3: 2800 mg Bamlanivimab + 2800 mg Etesevimab	0	518	0
other	Anaemia	Blood and lymphatic system disorders	Phase 3: Placebo	1	776	1
other	Anaemia	Blood and lymphatic system disorders	Phase 3: 700 mg Bamlanivimab + 1400 mg Etesevimab	4	513	4
other	Anaemia	Blood and lymphatic system disorders	Phase 3: Placebo For 350 mg Bamlanivimab + 700 mg Etesevimab	0	141	0
other	Anaemia	Blood and lymphatic system disorders	Phase 3: 350 mg Bamlanivimab + 700 mg Etesevimab	2	213	2
other	Anaemia	Blood and lymphatic system disorders	Phase 2/3: Bamlanivimab + Etesevimab (Pediatric Addendum, Arm 22)	0	94	0
other	Anaemia	Blood and lymphatic system disorders	Phase 2/3: Bebtelovimab (Pediatric Addendum, Arm 23)	0	17	0
other	Leukopenia	Blood and lymphatic system disorders	Phase 2: Placebo	0	156	0
other	Leukopenia	Blood and lymphatic system disorders	Phase 2: 700 mg Bamlanivimab	0	101	0
other	Leukopenia	Blood and lymphatic system disorders	Phase 2: 2800 mg Bamlanivimab	0	107	0
other	Leukopenia	Blood and lymphatic system disorders	Phase 2: 7000 mg Bamlanivimab	0	101	0
other	Leukopenia	Blood and lymphatic system disorders	Phase 2: 2800 mg Bamlanivimab + 2800 mg Etesevimab	0	112	0
other	Leukopenia	Blood and lymphatic system disorders	Phase 3: 2800 mg Bamlanivimab + 2800 mg Etesevimab	0	518	0
other	Leukopenia	Blood and lymphatic system disorders	Phase 3: Placebo	0	776	0
other	Leukopenia	Blood and lymphatic system disorders	Phase 3: 700 mg Bamlanivimab + 1400 mg Etesevimab	1	513	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04427501/events

API reference For AI assistants

Adverse events4,452

Sources 3

Read this list from software.